

Grifols Group enters into agreement with Canadian Plasma Resources to secure plasma supply in Canada

- *Grifols Group, in addition to its agreement with Canadian Plasma Resources, also plans to open its own plasma donation centers in Canada*
- *Latest Grifols Group actions, which deepen the company's commitment to Canada and its patients, will fulfill its current agreement with Canadian Blood Services to increase Canada's self-sufficiency in immunoglobulin medicines*

Barcelona, Spain, June 8, 2023 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with Canadian Plasma Resources (CPR), a Canadian plasma collector licensed by Health Canada, under which Grifols Group has the right to obtain plasma donated in CPR centers. Grifols Group has the intention to acquire CPR centers by the end of 2025.

Separate from its CPR agreement, Grifols Group also plans to open more plasma donation centers in Canada, expanding on its first, acquired in Winnipeg, Manitoba, in early 2022, and a second currently under development in Edmonton, Alberta. It expects to open as many as five additional centers in the country and is exploring potential locations in Ontario, where Grifols Group would operate as an “agent” of Canadian Blood Services per exemption under the province’s Voluntary Blood Donations Act. Precise locations for the Ontario centers, subject to prior approval by Canadian Blood Services, also depend on criteria such as population density, local talent pool and transport links. The Alberta and Ontario centers are expected to be operational in 2024. There are no current plans for locations in British Columbia.

The plasma Grifols Group collects in Canada will support the company’s long-term collaboration agreement with Canadian Blood Services, announced in September 2022, to increase Canada’s self-sufficiency in immunoglobulin (Ig) medicines through an all-Canadian supply chain. Grifols Group is working with Canadian Blood Services to steadily increase sourcing of the Canadian plasma necessary so that volumes eventually reach the agreed-to 600,000 liters to manufacture 2.4 million grams of Ig treatments annually by 2026. Production is exclusively for Canadian Blood Services and Canadian patients.

“Grifols Group is moving full speed ahead on its commitment to Canadian Blood Services, helping Canada achieve self-sufficiency for the patients there who depend on lifesaving plasma therapies,” said Raimon Grifols, Grifols Chief Corporate Officer. “We’re ensuring that all available Canadian plasma output that we obtain remains in Canada and is manufactured into medicines in Canada to support patients in Canada.”

GRIFOLS

Grifols' latest moves deepen its more than three-decade commitment to Canada and its patients who rely on the company's products. In 2020, Grifols Group invested more than USD 400 million in its Montreal plasma manufacturing site, which includes a fractionation plant with a capacity of 1.5 million liters and two purification plants. This facility, which will produce Ig for Canadian Blood Services, represents Canada's first and only large-scale plasma fractionation complex.

All Grifols Group operations in Canada will meet the regulatory and licensing requirements of Health Canada.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

International

FGS Global

Email: Grifols@fgsglobal.com

Tel.: +44 20 7251 3801

Spain

Duomo Communication

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel.: +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel.: 650 40 22 25

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

GRIFOLS

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.